AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2009-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT00867685
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00868231
- Locations
- 🇩🇪
Almirall Investigational Site #1, Berlin, Germany
🇩🇪Almirall Investigational Site #2, Grosshansdorf, Germany
AZD8566 Food Effect/Microtracer Study
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2009-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT00866385
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
Completed
- Conditions
- Nosocomial Infection
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00864929
- Locations
- 🇻🇳
Research Site, HCM, Vietnam
Renal Impairment Study
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT00863161
- Locations
- 🇸🇪
Research Site, Lulea, Sweden
🇸🇪Research, Uppsala, Sweden
Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 310
- Registration Number
- NCT00861016
Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2009-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00861718
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00860353
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2009-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00860821
- Locations
- 🇸🇪
Research Site, Malmö, Sweden
Faslodex Post Marketing Surveillance
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00860561
- Locations
- 🇰🇷
Research Site, Suwon-si, Korea, Republic of